Slide 1: Market-leading monitoring solutions - Big Technologies PLC Investor Presentation
Market-leading monitoring Big solutions Technologies PLC Investor Presentation May/June 2025
Slide 2: Agenda
Agenda 1. Our Mission Ian Johnson – CEO 2. 2024 Highlights Ian Johnson Ian Johnson – CEO CEO 3. Operational Highlights Ian Johnson – CEO 4. Financial Highlights Mike Johns – CFO 5. Litigation Summary Mike Johns Mike Johns – CFO CFO 6. Medium Term Focus and Outlook Ian Johnson - CEO 2
Slide 3: Our Mission
Our Mission buddi.
Slide 4: Our Mission – Creating a Safer World
Our Mission – Creating a Safer World • Market leading technology for Criminal Justice & Remote Care • Trusted provider of electronic monitoring products and services • Providing accurate real-time information to track individuals • We build long-term relationships with Governments, Police forces & P
Slide 5: 2024 Highlights
2024 Highlights buddi.
Slide 6: 2024 Highlights
2024 Highlights Continued progress in expanding market share and introducing new technology Criminal GainingJustice - traction with 50 new customers contributing to our US sales in 2024 New product Remote Care - Smart Tag 5.1; Alco Tag; Sure Tag; Mini+; SmartBeacon ID introductions RHighly & D – pro
Slide 7: Operational Highlights
Operational Highlights buddi.
Slide 8: Big Technologies plc (Buddi)
Big Technologies plc (Buddi) • Cloud based monitoring software platform (Buddi Eagle) Integrated technology platform for remote • Suite of modular hardware (GPS, RF, alcohol, biometric) monitoring of individuals • Real-time monitoring of individuals; high accuracy and reliability • Tens of thousands
Slide 9: Our Solutions
Our Solutions ° We proudly J | design and 7 fi = manufacture all our products in the UK.
Slide 10: Financial Highlights
Financial Highlights buddi.
Slide 11: Financial Highlights
Financial Highlights Strong base from which to drive the business forward £4.0m monthly recurring revenue • Recurring revenue provides strong revenue visibility and good margins 68% gross margins (2023: 71%) • Buddi’s market leading products command high gross margins, providing a firm foundation fo
Slide 12: Financial Highlights
Financial Highlights Targeted profitable growth through capitalisation of revenue opportunity and discipline on cost base 4% revenue growth ex Colombia contract on a constant currency basis • Strong underlying customer base bringing growth as contracts expand 63% of revenue from top 5 contracts (202
Slide 13: Litigation Update
Litigation Update buddi.
Slide 14: Litigation Summary
Litigation Summary • The Group has recognised a contingent liability in relation to the incoming litigation brought by former shareholders of Buddi Limited • Estimated legal fees to trial in June 2026 are provided for at the end of 2024 (£6.8m) • The Group commenced proceedings against Sara Murray f
Slide 15: Summary
Summary buddi.
Slide 16: Medium Term Focus and Outlook
Medium Term Focus and Outlook Criminal Justice Criminal - Justice Main focus - Expansion of US domestic sales team to address opportunities R&D– Positive market reception to alcohol detection combined with location – over R&D 500 units deployed with customers MM &A& –A Continuing dialogue on opportu
Slide 17: Appendix
Appendix buddi.
Slide 18: Profit and Loss
Profit and Loss High underlying margins FY 2024 FY 2023 £’000 £’000 Revenue 50,308 55,223 Cost of Sales (16,069) (16,176) Gross Profit 34,239 39,047 Gross Profit Margin 68.1% 70.7% Adjusted Administrative Expenses (ex Depn & Amort) (7,237) (6,042) Adjusted EBITDA 27,002 33,005 Adjusted EBITDA margin
Slide 19: Balance Sheet
Balance Sheet Robust balance sheet underpinned by strong cash position 31 Dec 24 31 Dec 23 £’000 £’000 Goodwill and intangible assets 18,209 19,027 Property, plant and equipment and right of use assets 6,834 6,775 Other non-current assets 1,349 583 Total non-current assets 26,392 26,385 Inventories
Slide 20: Cash flow
Cash flow Highly cash generative business providing stability in face of ongoing litigation FY 2024 FY 2023 £’000 £’000 Cash generated from operations 20,411 31,748 Taxes Paid (3,656) (3,739) Cash generated from operating activities 16,755 28,009 Own work capitalised (4,336) (4,303) Interest receive
Slide 21: Board – Refreshed Executive Team
Board – Refreshed Executive Team Ian Johnson, Chief Executive Officer Ian has spent his business career in life science and was founder and CEO of Biotrace International PLC, which was a listed company until its sale to 3M in December 2006. In addition to his current role as Executive Chairman of NI